5-<8-(3,4,5-triphenyl-1H-pyrazol-1-yl)octyl>-2H-tetrazole | 134702-04-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-<8-(3,4,5-triphenyl-1H-pyrazol-1-yl)octyl>-2H-tetrazole
• 英文别名: 5-[8-(3,4,5-Triphenyl-lH-pyrazol-1-yl)octyl]-2 H-tetrazole；5-[8-(3,4,5-triphenylpyrazol-1-yl)octyl]-2H-tetrazole
• CAS: 134702-04-8
• 化学式: C₃₀H₃₂N₆
• 分子量: 476.624
• InChiKey: JRHOPJFJXNXYJF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.4
• 重原子数：
  36
• 可旋转键数：
  12
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  72.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  1-(8-bromooctyl)-3,4,5-triphenyl-lH-pyrazole 在 potassium fluoride 、 三正丁基叠氮化锡 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 84.5h， 生成 5-<8-(3,4,5-triphenyl-1H-pyrazol-1-yl)octyl>-2H-tetrazole
  参考文献：
  名称：

  Structure-activity relationships associated with 3,4,5-triphenyl-1H-pyrazole-1-nonanoic acid, a nonprostanoid prostacyclin mimetic

  摘要：

  A series of phenylated pyrazoloalkanoic acid derivatives were synthesized and evaluated as inhibitors of ADP-induced human platelet aggregation. 3,4,5-Triphenyl-1H-pyrazole-1-nonanoic acid (8d), with an 1C50 of 0.4-mu-M, was the most potent inhibitor identified in this study. Biochemical studies determined that 8d increased intraplatelet cAMP accumulation and stimulated platelet membrane-bound adenylate cyclase in a concentration-dependent fashion. Displacement of [H-3]iloprost by 8d from platelet membranes indicated that the platelet prostacyclin (PGI2) receptor is the locus of biological action. Structure-activity studies demonstrated that the minimum structural requirements for binding to the platelet PGI2 receptor and inhibition of ADP-induced platelet aggregation within this series are a vicinally diphenylated pyrazole substituted with an omega-alkanoic acid side chain eight or nine atoms long. Potency depended upon both side-chain length and its topological relationship with the two phenyl rings.

  DOI：

  10.1021/jm00080a028

文献信息

• Arylpyrazol derivatives as anti-platelet agents, compositions and use
  申请人：Bristol-Myers Squibb Company

  公开号：US04994482A1

  公开（公告）日：1991-02-19

  Compounds of the formula ##STR1## wherein R.sup.1 and R.sup.2 each are independently hydrogen or phenyl, provided that R.sup.1 and R.sup.2 may not both be hydrogen; m is an integer from 3 to 9; n is an integer from 0 to 3 and the sum of m+n is an integer from 5 to 12; Z is O, S, SO, SO.sub.2, --CH.dbd.CH-- or a direct bond; A is ##STR2## R.sup.3 is hydrogen or C.sub.1-6 alkyl; and R.sup.4 is hydrogen, C.sub.1-4 alkyl or methylsulfonyl; and pharmaceutically acceptable salts or hydrates thereof are novel inhibitors of adenosine diphosphate and collagen-induced aggregation of human platelet-rich plasma and are particularly useful as inhibitors of mammalian blood platelet aggregation.

  式为##STR1##的化合物，其中R.sup.1和R.sup.2各自独立地为氢或苯基，但R.sup.1和R.sup.2不能同时为氢；m为3至9的整数；n为0至3的整数，m+n的和为5至12的整数；Z为O、S、SO、SO.sub.2、--CH.dbd.CH--或直接键；A为##STR2##R.sup.3为氢或C.sub.1-6烷基；R.sup.4为氢、C.sub.1-4烷基或甲基磺酰基。其药学上可接受的盐或水合物是人血小板富集血浆腺苷酸二磷酸和胶原诱导聚集的新型抑制剂，特别适用于哺乳动物血小板聚集的抑制剂。
• Arylpyrazole derivatives as platelet aggregation inhibitors
  申请人：Bristol-Myers Squibb Company

  公开号：EP0417449B1

  公开（公告）日：1995-02-15
• US4994482A
  申请人：——

  公开号：US4994482A

  公开（公告）日：1991-02-19
• US5071866A
  申请人：——

  公开号：US5071866A

  公开（公告）日：1991-12-10
• Structure-activity relationships associated with 3,4,5-triphenyl-1H-pyrazole-1-nonanoic acid, a nonprostanoid prostacyclin mimetic
  作者：Nicholas A. Meanwell、Michael J. Rosenfeld、J. J. Kim Wright、Catherine L. Brassard、John O. Buchanan、Marianne E. Federici、J. Stuart Fleming、Steven M. Seiler

  DOI：10.1021/jm00080a028

  日期：1992.1

  A series of phenylated pyrazoloalkanoic acid derivatives were synthesized and evaluated as inhibitors of ADP-induced human platelet aggregation. 3,4,5-Triphenyl-1H-pyrazole-1-nonanoic acid (8d), with an 1C50 of 0.4-mu-M, was the most potent inhibitor identified in this study. Biochemical studies determined that 8d increased intraplatelet cAMP accumulation and stimulated platelet membrane-bound adenylate cyclase in a concentration-dependent fashion. Displacement of [H-3]iloprost by 8d from platelet membranes indicated that the platelet prostacyclin (PGI2) receptor is the locus of biological action. Structure-activity studies demonstrated that the minimum structural requirements for binding to the platelet PGI2 receptor and inhibition of ADP-induced platelet aggregation within this series are a vicinally diphenylated pyrazole substituted with an omega-alkanoic acid side chain eight or nine atoms long. Potency depended upon both side-chain length and its topological relationship with the two phenyl rings.